A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria hypertension and diabetes in a remote Aboriginal Australian community 2008–2013

摘要

IntroductionWe conducted a double-blind randomised controlled trial in a remote-living Australian Aboriginal group at high risk for chronic disease to assess whether pharmacological treatment with angiotensin converting enzyme inhibitor (ACEi) could delay the onset of albuminuria, hypertension or diabetes in people currently free of those conditions.